Physician profile
David M Gilbert
NPI 1033178082
$1,324.33
in general payments reported to CMS, 2019-2025
17 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.94 · 2020: $53.93 · 2021: $28.98 · 2022: $272 · 2023: $178 · 2024: $341 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Entertainment: $32.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.21 |
| Entertainment | $32.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $372.93 | 2019-2025 | Myday Contact Lens, Biofinity Contact Lens, Clariti Contact Lens |
| Dompe US, INC. | $283.66 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $225.11 | 2023-2025 | Precision 1, Precision 7, Dailies Total1 |
| Optos, INC. | $66.98 | 2020-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $57.27 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $55.30 | 2022-2025 | |
| Topcon Healthcare, INC. | $35.63 | 2019 | |
| Harrow Eye, LLC | $32.02 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $30.50 | 2022 | |
| Tearlab Corp | $28.93 | 2024 | Scoutpro Osmolarity System |
| Tarsus Pharmaceuticals, INC. | $23.84 | 2024 | Xdemvy |
| Spark Therapeutics, INC. | $22.59 | 2022 | |
| Oyster Point Pharma, INC. | $21.26 | 2022 | |
| Abb Con-Cise Optical Group LLC | $20.00 | 2023 | Spectacle Lenses, Contact Lens |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.83 | 2022 | |
| Allergan, INC. | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.